



Position Statement on Prescription Drug Recalls

Approved by the ACP Board of Regents on April 20, 2020

- 1. In order to adequately protect the health and safety of patients from defective and harmful drugs, a national recall notification network should inform health professionals of all clinically important recalls that have bearing on patient care.**
- 2. Thorough electronic tracking of pharmaceutical products and their components throughout the supply chain is needed to be able to promptly identify and notify those impacted by recalled products.**
- 3. Regulatory agencies should have increased authority to intervene in the production and supply of pharmaceutical products that are known to be defective and cause harm to patients.**
- 4. Health plans and pharmacy benefit managers should provide a process for expedited formulary exceptions in the event of a recall of a generic medication and ensure affordable patient access to the brand medication or alternative treatment options.**